Reflecting that TP53 mutant AML patients demonstrate chemoresistance and poor long-term survival, modern recommendations now prioritize early referral for clinical trials and in some cases even consider it a frontline recommendation for these patients [240,246]. This evidence concerns the gene TP53 and acute myeloid leukemia.